Literature DB >> 28236625

Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia.

Martin Overgaard1, Susanne Møller Pedersen1.   

Abstract

BACKGROUND: Hyperprolactinemia diagnosis and treatment is often compromised by the presence of biologically inactive and clinically irrelevant higher-molecular-weight complexes of prolactin, macroprolactin. The objective of this study was to evaluate the performance of two macroprolactin screening regimes across commonly used automated immunoassay platforms.
METHODS: Parametric total and monomeric gender-specific reference intervals were determined for six immunoassay methods using female (n=96) and male sera (n=127) from healthy donors. The reference intervals were validated using 27 hyperprolactinemic and macroprolactinemic sera, whose presence of monomeric and macroforms of prolactin were determined using gel filtration chromatography (GFC).
RESULTS: Normative data for six prolactin assays included the range of values (2.5th-97.5th percentiles). Validation sera (hyperprolactinemic and macroprolactinemic; n=27) showed higher discordant classification [mean=2.8; 95% confidence interval (CI) 1.2-4.4] for the monomer reference interval method compared to the post-polyethylene glycol (PEG) recovery cutoff method (mean=1.8; 95% CI 0.8-2.8). The two monomer/macroprolactin discrimination methods did not differ significantly (p=0.089). Among macroprolactinemic sera evaluated by both discrimination methods, the Cobas and Architect/Kryptor prolactin assays showed the lowest and the highest number of misclassifications, respectively.
CONCLUSIONS: Current automated immunoassays for prolactin testing require macroprolactin screening methods based on PEG precipitation in order to discriminate truly from falsely elevated serum prolactin. While the recovery cutoff and monomeric reference interval macroprolactin screening methods demonstrate similar discriminative ability, the latter method also provides the clinician with an easy interpretable monomeric prolactin concentration along with a monomeric reference interval.

Entities:  

Keywords:  assay interference; hyperprolactinemia; immunoassay; macroprolactinemia; polyethylene glycol precipitation; reference interval

Mesh:

Substances:

Year:  2017        PMID: 28236625     DOI: 10.1515/cclm-2016-0902

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

Review 1.  Biochemical diagnosis in prolactinomas: some caveats.

Authors:  Stephan Petersenn
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

2.  Prevalence and reproductive manifestations of macroprolactinemia.

Authors:  Amanpreet Kaur Kalsi; Ashutosh Halder; Manish Jain; P K Chaturvedi; J B Sharma
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

3.  Macro-TSH: A Diagnostic Challenge.

Authors:  Camilla Bøgelund Larsen; Eva Rabing Brix Petersen; Martin Overgaard; Steen Joop Bonnema
Journal:  Eur Thyroid J       Date:  2020-08-21

4.  Antipsychotics-induced hyperprolactinemia and screening for macroprolactin.

Authors:  Nedjeljka Ruljancic; Ana Bakliza; Sandra Vuk Pisk; Natko Geres; Katarina Matic; Ena Ivezic; Vladimir Grosic; Igor Filipcic
Journal:  Biochem Med (Zagreb)       Date:  2020-12-15       Impact factor: 2.313

5.  The validation of macroprolactin analysis by polyethylene glycol precipitation using Fujirebio Lumipulse.

Authors:  Febe C Vermue; Richard Heesen; Douwe de Boer; Judith Bons; Sjoerd A A van den Berg
Journal:  Pract Lab Med       Date:  2022-07-13

6.  Reference intervals of the sex hormonal profile in healthy women: A retrospective single-center study in Peru.

Authors:  Jeel Moya-Salazar; Sandra P Cerda; Betsy Cañari; Marcia M Moya-Salazar; Hans Contreras-Pulache
Journal:  Heliyon       Date:  2022-09-08

Review 7.  Hormone Immunoassay Interference: A 2021 Update.

Authors:  Khaldoun Ghazal; Severine Brabant; Dominique Prie; Marie-Liesse Piketty
Journal:  Ann Lab Med       Date:  2022-01-01       Impact factor: 3.464

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.